Vanda Pharmaceuticals Inc. (VNDA), Friday announced that the FDA has requested, and the company has agreed to, a brief extension of the expedited re-review of the partial clinical hold on long-term studies of tradipitant in motion sickness, moving the target completion date from November 26, 2025, to December 5, 2025.
Separately, the FDA has issued labelling comments and formal discussions have begun for the New Drug Application (NDA) of tradipitant for the prevention of vomiting induced by motion.
The PDUFA target action date remains December 30, 2025.
Tradipitant is a neurokinin-1 receptor antagonist licensed from Eli Lilly and is in development for multiple indications, including gastroparesis, motion sickness, and nausea and vomiting associated with GLP-1 receptor agonists.
Vanda recently reported positive Phase 2 results showing tradipitant reduced GLP-1 agonist- induced nausea and vomiting, positioning it as a potential adjunct therapy in the fast-growing GLP-1 market.
VNDA closed Friday's trading session at $5.36, up 1.13%. Over the past 12 months the stock has traded between $3.81 to $5.70.
For comments and feedback contact: editorial@rttnews.com
Business News
May 22, 2026 14:46 ET Minutes of the latest Fed policy session was the highlight of the week along with survey data on the U.S. housing market. In Europe, survey data signaled the trends in the euro area private sector. Further, consumer price inflation data from the U.K. was in focus. In Asia, various economic indicators from China drew attention to the health of the economy.